報價延遲最少15分鐘:2025/05/30 15:02 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
65.5 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.36/-1.93
|
|
企業價值
2.14B
|
| 資產負債 |
|
每股賬面淨值
4.86
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/30 15:02 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. |